Immunofluorescence detection of globotriaosylceramide deposits in conjunctival biopsies of fabry disease patients

Clinical and Experimental Ophthalmology

Volumn 34, Issue 7, 2006, Pages 689-694

  Rozenfeld, Paula A ^a   Croxatto, Oscar ^b   Ebner, Roberto ^b   Fossati, Carlos A ^a  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^b HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

Author keywords

Conjunctiva; Fabry disease; Fluorescent antibody technique; Globotriaosylceramide

Indexed keywords

AGALSIDASE ALFA; GLOBOTRIAOSYLCERAMIDE; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONJUNCTIVAL BIOPSY; CONTROLLED STUDY; ENZYME REPLACEMENT; FABRY DISEASE; FAMILIAL DISEASE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; MALE; RELIABILITY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BIOPSY; CONJUNCTIVA; CONJUNCTIVAL DISEASES; FABRY DISEASE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MALE; MIDDLE AGED; TRIHEXOSYLCERAMIDES;

EID: 33748530605     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2006.01318.x     Document Type: Article

References (31)

1. Brady RO, Gal AE, Bradley RM et al. Enzymatic defect in Fabry disease. N Engl J Med 1967; 276: 1163-7.
2. Kint JA. Fabry disease. Alpha galactosidase deficiency. Science 1970; 167: 1268-9.
3. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WX, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 1995; 2741-84.
4. Spaeth GL, Frost P. Fabry disease. Its ocular manifestations. Arch Ophthalmol 1969; 74: 760-9.
5. Ries M, Gupta S, Moore D et al. Pediatric Fabry disease. Pediatrics 2005; 115: E344-55.
6. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38: 750-60.
7. Whybra C, Kampmann C, Willers I. Anderson-Fabry disease: Clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001; 24: 715-24.
8. Orssaud C, Dufier J, Germain D. Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. Ophthalmic Genet 2003; 24: 129-39.
9. Nguyen T, Gin T, Nicholls K, Low M, Galanos J, Crawford A. Ophtalmologic manifestations of Fabry disease: A survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Experiment Ophthalmol 2005; 33: 164-8.
10. Fumex-Boizard L, Cochat P, Fouilhoux A, Guffon N, Denis P. Relation between ocular manifestations and organ involvement in ten patients with Fabry disease. J Fr Ophtalmol 2005;28: 45-50.
11. Ries M, Ramaswami U, Parini R etal. The early clinical phenotype of Fabry disease: A study on 35 European children and adolescents. Eur J Pediatr 2001; 162: 767-72.
12. Schiffmann R, Kopp JB, Austin HA 3rd etal. Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 2001; 285: 2743-9.
13. Desnick RJ, Allen YK, Desnick S et al. Fabry's disease: Enzymatic diagnosis of hemyzigotes and heterozygotes. α-Galactosidase A activities in plasma, serum, urine and leukocytes. J Lab Clin Med 1973; 81: 157-71.
14. Chamoles NA, Blanco M, Gaggioli D. Fabry disease: Enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 2001; 308: 195-6.
15. Spence MW, Goldbloom AL, Burgness JK et al. Heterozygote detection in angiokeratoma corporis diffusum (Anderson-Fabry disease). J Med Genet 1977; 14: 91-9.
16. Hozumi I, Nishizawa M, Ariga T et al. Biochemical and clinical analysis of accumulated glycolipids in symptomatic heterozygotes of angiokeratoma corporis diffusum (Fabry's disease) in comparison with hemizygotes. J Lipid Res 1990; 31: 335-40.
17. Desnick RJ, Sweeley CC, Krivit W. A method for the quantitative determination of neutral glycosphingolipids in urine sediment. J Lipid Res 1970; 11: 31-7.
18. Cable WJL, McCluer RH, Kolodny EH et al. Fabry disease: Detection of heterozygotes by examination of glycolipids in urinary sediment. Neurology 1982; 32: 1139-45.
19. Weingeist TA, Blodi FC. Fabry disease: Ocular findings in a female carrier. Alight and electron microscopic study. Arch Ophthalmol 1971; 85: 169-76.
20. Font RL, Fine BS. Ocular pathology in Fabry disease. Histochemical and electron microscopic examination. Am J Ophthalmol 1972; 73: 419-30.
21. Macrae WG, Ghosh M, McCulloch C. Corneal changes in Fabry disease: A clinico-pathologic case report of a heterozygote. Ophthalmic Paediatr Genet 1985; 5: 185-90.
22. Lyon MF. Sex chromatin and gene action in the mammalian X-chromosome. Am J Hum Genet 1962; 14: 135-48.
23. Garman SC, Garboczi DN. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol 2004; 337: 319-35.
24. Schäfer E, Baron K, Widmer U et al. Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. Hum Mutat 2005; 25: 412-18.
25. Oosterwijk E, Kalisiak A, Wakka JC etal. Monoclonal antibodies against Galα1-4Galβ1-4Glc (Pk, CD 77) produced with a synthetic glycoconjugate as immunogen: Reactivity with carbohydrates, with fresh frozen human tissues and hematopoietic tumors. Int J Cancer 1991; 48: 848-54.
26. Kotani M, Ozawa H, Kawashima I et al. Generation of one set of monoclonal antibodies specific for a-pathway ganglio-series gangliosides. Biochim Biophys Acta 1992; 1117: 97-103.
27. Itoh K, Takenaka T, Nakao S et al. Immunofluorescence analysis of trihexosylceramide accumulated in the hearts of variant hemizygotes and heterozygotes with Fabry disease. Am J Cardiol 1996; 78: 116-17.
28. Fukushima M, Tsuchiyama Y, Nakato T et al. A female heterozygous patient with Fabry's disease with renal accumulation of trihexosylceramide detected with a monoclonal antibody. Am J Kidney Dis 1995; 26: 952-5.
29. Kanekura T, Fukushige T, Kanda A etal. Immunoelectron-microscopic detection of globotriaosylceramide accumulated in the skin of patients with Fabry disease. Br J Dermatol 2005; 153: 544-8.
30. Thurberg BL, Rennke H, Colvin RB et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002; 62: 1933-46.
31. Thurberg BL, Randolph Byers H, Granter SR et al. Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 2004; 122: 900-8.